12.74

1.76% 0.22

Lyell Immunopharma Inc (LYEL)

Overview News Price History Option Chain Financials Discussions Forecast

Lyell Immunopharma Inc stock is traded at $12.74, with a volume of 359.96K. It is up +1.76% in the last 24 hours and down -22.83% over the past month. Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Previous Close:

$12.52

Open:

$12.73

24h Volume:

359.96K

Relative Volume:

3.72

Market Cap:

$297.28M

Revenue:

$31,000

Net Income/Loss:

$-246.41M

P/E Ratio:

-1.0002

EPS:

-12.7377

Net Cash Flow:

$-134.42M

1W Performance:

-7.14%

1M Performance:

-22.83%

6M Performance:

-60.65%

1Y Performance:

+32.99%

1-Day Range:

$12.24

$13.22

1-Week Range:

$12.03

$13.96

52-Week Range:

$8.46

$45.00

Lyell Immunopharma Inc Stock (LYEL) Company Profile

Name

Lyell Immunopharma Inc

Sector

Healthcare (1104)

Industry

Biotechnology (617)

Phone

650 695-0677

Address

201 HASKINS WAY, SOUTH SAN FRANCISCO

Employee

161

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

LYEL's Discussions on Twitter

Compare LYEL vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LYEL Lyell Immunopharma Inc	12.74	297.28M	31,000	-246.41M	-134.42M	-12.74
VRTX Vertex Pharmaceuticals Inc	451.63	114.63B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.13B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	34.65B	742.00K	-1.37B	-1.07B	-7.0731

Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Needham	Buy
Mar-09-26	Initiated	Citizens	Mkt Outperform
Dec-09-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-30-24	Downgrade	BofA Securities	Buy → Underperform
Jun-27-24	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-28-23	Downgrade	JP Morgan	Overweight → Neutral
Nov-14-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-11-22	Downgrade	Goldman	Buy → Neutral
Oct-17-22	Initiated	H.C. Wainwright	Buy
Jul-12-21	Initiated	BofA Securities	Buy
Jul-12-21	Initiated	Goldman	Buy
Jul-12-21	Initiated	JP Morgan	Overweight
Jul-12-21	Initiated	Morgan Stanley	Overweight

View All

Lyell Immunopharma Inc Stock (LYEL) Latest News

Jun 18, 2026

Lyell Immunopharma (LYEL) major holder transfers shares as commission - Stock Titan

Jun 18, 2026

Innovative Cellular Therapeutics (LYEL) crosses 12.3% ownership after milestone - Stock Titan

Jun 18, 2026

Innovative Cellular Therapeutics (LYEL partner) reports 3M Lyell Immunopharma shares - Stock Titan

Jun 18, 2026

Jun 17, 2026